Literature DB >> 19481333

Classification of male lower urinary tract symptoms using mathematical modelling and a regression tree algorithm of noninvasive near-infrared spectroscopy parameters.

Lynn Stothers1, Ramón Guevara, Andrew Macnab.   

Abstract

BACKGROUND: Assessment of bladder outlet obstruction (BOO) is standard clinical practice in patients with lower urinary tract symptoms (LUTS). This is currently achieved through pressure-flow studies. Research indicates that progressive functional impairment of the bladder due to BOO is associated with haemodynamic changes. Near-infrared spectroscopy (NIRS) is an optical method of monitoring tissue oxygenation and haemodynamics via changes in concentration of the chromophores oxyhaemoglobin (O(2)Hb) and deoxyhaemoglobin (HHb).
OBJECTIVE: To report a noninvasive technique and mathematic method of analysis for assessment of BOO in male subjects using NIRS and to test the independent ability of NIRS data to distinguish between patients with and without obstruction using a classification and regression tree algorithm (CART). DESIGN, SETTING, AND PARTICIPANTS: A prospective cohort study to evaluate subjects presenting for urodynamic assessment of LUTS using standard urodynamic studies with simultaneous transcutaneous NIRS monitoring. The NIRS data (magnitude and pattern of changes in O(2)Hb and HHb) were analysed, and a CART algorithm was constructed. Sixty-four males referred for evaluation of LUTS were studied at a tertiary care, university-based research and clinical facility. MEASUREMENTS: Clinical symptoms were classified using the International Prostate Symptom Score (IPSS). Pressure-flow studies were done with simultaneous transcutaneous NIRS monitoring of the detrusor. Pressure-flow studies were classified according to the Abrams-Griffiths nomogram. NIRS data documented changes in the concentration of the chromophores O(2)Hb and HHb. RESULTS AND LIMITATIONS: IPSS scores ranged from 12 to 34, with a mean of 19. The pressure-flow nomogram found 30 patients with BOO, 16 patients without BOO, and 18 patients with equivocal results. The CART found a misclassification error of 4% with 88% specificity and 94% precision. The NIRS instrument and algorithm were new; no asymptomatic subjects were studied.
CONCLUSION: Using a CART algorithm, noninvasive NIRS data during voiding had independent discriminatory ability related to classification of BOO. Copyright 2009 European Association of Urology. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Year:  2009        PMID: 19481333     DOI: 10.1016/j.eururo.2009.05.004

Source DB:  PubMed          Journal:  Eur Urol        ISSN: 0302-2838            Impact factor:   20.096


  6 in total

Review 1.  Imaging assessments of lower urinary tract dysfunctions: Future steps.

Authors:  Fawzy F Farag; John Heesakkers
Journal:  Turk J Urol       Date:  2014-06

2.  New Diagnostics for Male Lower Urinary Tract Symptoms.

Authors:  Natalie R Swavely; John E Speich; Lynn Stothers; Adam P Klausner
Journal:  Curr Bladder Dysfunct Rep       Date:  2019-05-03

3.  Probing penile hemodynamics by using photoplethysmography as objective indicators for male erection quality and sexual function.

Authors:  Yuan-Hung Pong; Yi-Kai Chang; Ching-En Hsu; Po-Cheng Chen; Yu-Chuan Lu; Vincent F S Tsai; Hong-Chiang Chang; Men-Tzung Lo; Chen Lin
Journal:  Sci Rep       Date:  2021-06-08       Impact factor: 4.379

4.  Monitoring Detrusor Oxygenation and Hemodynamics Noninvasively during Dysfunctional Voiding.

Authors:  Andrew J Macnab; Lynn S Stothers; Babak Shadgan
Journal:  Adv Urol       Date:  2012-09-18

5.  Near-infrared spectroscopy of the urinary bladder during voiding in men with lower urinary tract symptoms: a preliminary study.

Authors:  Fawzy F Farag; Joseph Meletiadis; Mohamad D Saleem; Wout F Feitz; John P Heesakkers
Journal:  Biomed Res Int       Date:  2013-07-14       Impact factor: 3.411

6.  Assessment of BPH/BOO.

Authors:  Altaf Mangera; Nadir I Osman; Christopher R Chapple
Journal:  Indian J Urol       Date:  2014-04
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.